FRI066 Treatment History And Comorbidities Reported By Patients With Hypothalamic Obesity Treated With Setmelanotide In A Phase 2 Trial

Disclosure: C.L. Roth: Other; Self; Study funding from Rhythm Pharmaceuticals, Inc. A.H. Shoemaker: Advisory Board Member; Self; Rhythm Pharmaceuticals, Inc., Saniona. Other; Self; Study funding from Rhythm Pharmaceuticals, Inc. M. Gottschalk: Advisory Board Member; Self; Rhythm Pharmaceuticals, Inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Roth, Christian L, Shoemaker, Ashley H, Gottschalk, Michael, Miller, Jennifer, Yuan, Guojun, Malhotra, Sonali, Scimia, Cecilia, Jennifer Abuzzahab, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Adipose Tissue, Appetite, & Obesity
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555070/
http://dx.doi.org/10.1210/jendso/bvad114.076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555070/
http://dx.doi.org/10.1210/jendso/bvad114.076

Ejemplares similares